Quantcast

Latest Debiopharm Group Stories

2011-05-04 02:00:00

LAUSANNE, Switzerland and NEW HAVEN, Connecticut, May 4, 2011 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University (Yale), a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class...

2011-04-14 02:00:00

LAUSANNE, Switzerland and BANGALORE, India, April 14, 2011 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based drug discovery company, signed on March 23, 2011 an option and exclusive worldwide license agreement concerning the development and commercialisation of Debio 1142, a novel inhibitor of an...

2011-01-18 02:00:00

LAUSANNE, Switzerland, January 18, 2011 /PRNewswire/ -- Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Group(TM) announced today that Diagnoplex has closed a series A financing extension with Debiopharm Group(TM). Subject to certain milestones, Debiopharm Group(TM) has committed to invest a substantial amount in the company, half of which upfront. Investors in the CHF 10 million A-round were Novartis Venture Fund, NeoMed, and Initiative Capital...

2010-12-01 09:00:00

LAUSANNE, Switzerland, December 1, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today announced that it received the "2010 Frost & Sullivan European Biopharmaceuticals Company of the Year Award". This Award is presented each year to the company that has excelled in the following criteria: growth strategy excellence,...

2010-12-01 03:30:00

LONDON, Dec. 1, 2010 /PRNewswire/ -- The 2010 Frost & Sullivan Europe Company of the Year Award in Biopharmaceuticals is presented to Debiopharm Group(TM) (Debiopharm). (Logo: http://photos.prnewswire.com/prnh/20081117/FSLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO) Debiopharm has a business model of in-licensing new molecules from biotech companies, pharmaceutical and start up companies as well as academic institutions based worldwide. It then adds value through...

2010-11-23 08:00:00

LAUSANNE, Switzerland, November 23, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), an independent specialist in global bio-pharmaceutical development in the field of oncology and regarding certain serious diseases, has announced the winner of the Prix Debiopharm Valais pour les Sciences de la Vie (Debiopharm Valais Life Sciences Prize). This year, Abionic S.A., represented by its founder and executive director Dr Nicolas Durand, won the prize for a new diagnostic platform, the...

2010-09-24 01:59:00

LAUSANNE, Switzerland, September 24, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today presented the 'The JCA-Mauvernay Award' to Doctor Seishi Ogawa from the University of Tokyo, for his research on cancer genome analysis and to Professor Shin Maeda from Yokohama City University of Medicine, for his research on liver...

2010-09-13 02:00:00

LAUSANNE, Switzerland, and BANGALORE, India, Sept. 13 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd. (Aurigene), a Bangalore-based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre-IND drug...

2010-09-02 11:10:00

LAUSANNE, Switzerland, September 2, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, today announced that the 'Debiopharm Life Sciences Award 2010' went to Professor Jean-Christophe Leroux for his innovative research on polymer chemistry, nanotechnology and pharmaceutical sciences to yield novel drug therapies. This year, the...

2010-04-27 06:59:00

LAUSANNE, Switzerland, April 27, 2010 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalised medicine, today announced that it has started patient enrolment in its Phase I clinical trial for the small molecule inhibitor of...


Word of the Day
virgule
  • A punctuation mark (/) used to separate related items of information.
  • A little rod; a twig.
This word comes from the Late Latin 'virgula,' accentual mark, a diminutive of 'virga,' rod.
Related